GlassScriptPhysician profile
Katherine Williams
NPI 1740712249
$1,575.95
in general payments reported to CMS, 2019-2025
26 companies · $857 in 2025
The $857 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $101 · 2022: $14.88 · 2023: $86.89 · 2024: $516 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.21 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.44 | 2024-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $171.18 | 2025 | Yeztugo |
| Pfizer INC. | $124.10 | 2020-2025 | |
| Abbott Laboratories | $106.51 | 2022-2025 | Alere Determine Hiv1/2 Ag/Ab Combo, Freestyle Libre 3, Id Now Instrument |
| Glaxosmithkline, LLC. | $89.76 | 2024-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $89.65 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.92 | 2024 | Caplyta |
| Abbvie INC. | $84.03 | 2023-2025 | Vraylar |
| Astellas Pharma US INC | $66.61 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $58.68 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $56.43 | 2023-2025 | Korlym |
| Lilly USA, LLC | $44.20 | 2020-2025 | Mounjaro, Kisunla |
| Inspire Medical Systems, INC. | $43.80 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $37.86 | 2024 | |
| Dynavax Technologies Corporation | $32.49 | 2024-2025 | Heplisav-B |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $31.50 | 2023-2025 | Apretude |
| Axsome Therapeutics, INC. | $29.08 | 2024 | Auvelity |
| Vertex Pharmaceuticals Incorporated | $27.73 | 2025 | |
| Optinose US, INC. | $25.68 | 2025 | |
| Azurity Pharmaceuticals, INC. | $24.50 | 2025 | Azmiro |
| Allergan, INC. | $21.54 | 2020 | |
| Paratek Pharmaceuticals, INC. | $20.38 | 2025 | Xhance, Nuzyra |
| Otsuka America Pharmaceutical, INC. | $20.04 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $12.71 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $11.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.